| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
|
J Antimicrob Chemother
|
2009
|
1.43
|
|
2
|
Comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid".
|
J Acquir Immune Defic Syndr
|
2013
|
1.39
|
|
3
|
A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients.
|
J Chromatogr Sci
|
2008
|
1.33
|
|
4
|
Molecular typing of Mycobacterium bovis strains isolated in Italy from 2000 to 2006 and evaluation of variable-number tandem repeats for geographically optimized genotyping.
|
J Clin Microbiol
|
2009
|
1.33
|
|
5
|
Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.
|
AIDS
|
2010
|
1.24
|
|
6
|
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations.
|
Antimicrob Agents Chemother
|
2011
|
1.24
|
|
7
|
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir.
|
Clin Infect Dis
|
2008
|
1.22
|
|
8
|
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
|
Antivir Ther
|
2007
|
1.20
|
|
9
|
Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction.
|
J Infect Dis
|
2011
|
1.18
|
|
10
|
An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients.
|
Ther Drug Monit
|
2008
|
1.18
|
|
11
|
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.
|
PLoS One
|
2010
|
1.13
|
|
12
|
Lopinavir protein binding in vivo through the 12-hour dosing interval.
|
Ther Drug Monit
|
2004
|
1.12
|
|
13
|
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.
|
J Antimicrob Chemother
|
2006
|
1.11
|
|
14
|
Evaluation of a rapid antigen and antibody combination test in acute HIV infection.
|
J Clin Virol
|
2013
|
1.05
|
|
15
|
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1.
|
Clin Infect Dis
|
2013
|
1.04
|
|
16
|
Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.
|
Antimicrob Agents Chemother
|
2010
|
1.03
|
|
17
|
Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era.
|
Eur Heart J
|
2013
|
0.98
|
|
18
|
The relationship between nevirapine plasma concentrations and abnormal liver function tests.
|
AIDS Res Hum Retroviruses
|
2004
|
0.98
|
|
19
|
HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2007
|
0.94
|
|
20
|
Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?
|
J Antimicrob Chemother
|
2004
|
0.94
|
|
21
|
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation.
|
J Pharm Biomed Anal
|
2010
|
0.92
|
|
22
|
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study.
|
Retrovirology
|
2014
|
0.92
|
|
23
|
Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.
|
PLoS One
|
2013
|
0.91
|
|
24
|
Drug-drug interactions and tolerance in combining antituberculosis and antiretroviral therapy.
|
Expert Opin Drug Saf
|
2005
|
0.89
|
|
25
|
An improved HPLC fluorimetric method for the determination of enfuvirtide plasma levels in HIV-infected patients.
|
Ther Drug Monit
|
2006
|
0.89
|
|
26
|
HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions.
|
J Pharm Biomed Anal
|
2010
|
0.89
|
|
27
|
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment.
|
Ther Drug Monit
|
2012
|
0.88
|
|
28
|
Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2006
|
0.88
|
|
29
|
The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.
|
Br J Clin Pharmacol
|
2002
|
0.87
|
|
30
|
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism.
|
Pharmacogenet Genomics
|
2010
|
0.87
|
|
31
|
Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring.
|
AIDS
|
2003
|
0.86
|
|
32
|
Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting.
|
Ther Drug Monit
|
2002
|
0.86
|
|
33
|
Raltegravir penetration in seminal plasma of healthy volunteers.
|
Antimicrob Agents Chemother
|
2010
|
0.86
|
|
34
|
Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics.
|
AIDS
|
2002
|
0.86
|
|
35
|
Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers.
|
J Antimicrob Chemother
|
2012
|
0.86
|
|
36
|
Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.
|
Clin Pharmacokinet
|
2014
|
0.85
|
|
37
|
Generation of 8.5-fs pulses at 1.3 microm for ultrabroadband pump-probe spectroscopy.
|
Opt Express
|
2009
|
0.85
|
|
38
|
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.
|
Antimicrob Agents Chemother
|
2007
|
0.85
|
|
39
|
A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients.
|
Ther Drug Monit
|
2010
|
0.85
|
|
40
|
Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment.
|
Clin Infect Dis
|
2008
|
0.84
|
|
41
|
In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients.
|
Thromb Haemost
|
2013
|
0.83
|
|
42
|
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis.
|
J Antimicrob Chemother
|
2013
|
0.83
|
|
43
|
Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.
|
Br J Clin Pharmacol
|
2012
|
0.83
|
|
44
|
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens.
|
J Antimicrob Chemother
|
2010
|
0.83
|
|
45
|
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics.
|
AIDS
|
2012
|
0.81
|
|
46
|
Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.
|
J Acquir Immune Defic Syndr
|
2009
|
0.81
|
|
47
|
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage.
|
AIDS
|
2011
|
0.81
|
|
48
|
Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient.
|
J Antimicrob Chemother
|
2009
|
0.81
|
|
49
|
Experimental evaluation of a new system for laser tissue welding applied on damaged lungs.
|
Interact Cardiovasc Thorac Surg
|
2013
|
0.80
|
|
50
|
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.
|
J Antimicrob Chemother
|
2011
|
0.80
|
|
51
|
A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2006
|
0.80
|
|
52
|
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients.
|
J Pharm Biomed Anal
|
2012
|
0.80
|
|
53
|
Pharmacokinetics of saquinavir co-administered with cimetidine.
|
J Antimicrob Chemother
|
2002
|
0.80
|
|
54
|
Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide.
|
AIDS
|
2006
|
0.80
|
|
55
|
Wavefront correction and high-resolution in vivo OCT imaging with an objective integrated multi-actuator adaptive lens.
|
Opt Express
|
2015
|
0.80
|
|
56
|
Detection of stavudine concentrations in plasma of HIV-infected patients taking zidovudine.
|
AIDS
|
2004
|
0.80
|
|
57
|
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort.
|
J Acquir Immune Defic Syndr
|
2006
|
0.80
|
|
58
|
Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients.
|
AIDS
|
2010
|
0.80
|
|
59
|
Alpha 1-acid glycoprotein levels in human immunodeficiency virus-infected subjects on antiretroviral regimens.
|
Drug Metab Dispos
|
2002
|
0.80
|
|
60
|
Resolution of HCV infection after highly active antiretroviral therapy in a HIV-HCV coinfected patient.
|
J Infect
|
2006
|
0.79
|
|
61
|
Lopinavir measurement in pleural effusion in a human immunodeficiency virus type 1-infected patient with kaposi's sarcoma.
|
Antimicrob Agents Chemother
|
2002
|
0.79
|
|
62
|
Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta.
|
AIDS
|
2006
|
0.79
|
|
63
|
Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients.
|
Curr HIV Res
|
2009
|
0.79
|
|
64
|
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev.
|
Antimicrob Agents Chemother
|
2009
|
0.79
|
|
65
|
Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting.
|
Ther Drug Monit
|
2012
|
0.79
|
|
66
|
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
|
J Med Virol
|
2010
|
0.79
|
|
67
|
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells.
|
J Antimicrob Chemother
|
2012
|
0.79
|
|
68
|
Push-pull membrane mirrors for adaptive optics.
|
Opt Express
|
2006
|
0.78
|
|
69
|
Optimization of high-order harmonic generation by adaptive control of a sub-10-fs pulse wave front.
|
Opt Lett
|
2004
|
0.78
|
|
70
|
HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience.
|
J Acquir Immune Defic Syndr
|
2003
|
0.78
|
|
71
|
Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment.
|
Ther Drug Monit
|
2012
|
0.78
|
|
72
|
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.
|
J Antimicrob Chemother
|
2011
|
0.78
|
|
73
|
Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject.
|
Clin Infect Dis
|
2007
|
0.78
|
|
74
|
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection.
|
J Antimicrob Chemother
|
2014
|
0.77
|
|
75
|
Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment.
|
AIDS
|
2016
|
0.77
|
|
76
|
Raltegravir: is a 400 mg once-daily dose enough?
|
J Antimicrob Chemother
|
2010
|
0.77
|
|
77
|
Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
|
Antivir Ther
|
2006
|
0.77
|
|
78
|
Healthy ranges for alanine aminotransferase levels.
|
Ann Intern Med
|
2003
|
0.77
|
|
79
|
Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study.
|
J Cardiovasc Med (Hagerstown)
|
2017
|
0.77
|
|
80
|
Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural Burundi.
|
Br J Clin Pharmacol
|
2015
|
0.76
|
|
81
|
Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults.
|
AIDS
|
2015
|
0.76
|
|
82
|
Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction.
|
Pharmacogenomics
|
2014
|
0.76
|
|
83
|
Heart failure in patients with human immunodeficiency virus: a review of the literature.
|
J Cardiovasc Med (Hagerstown)
|
2015
|
0.76
|
|
84
|
Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients.
|
J Antimicrob Chemother
|
2013
|
0.76
|
|
85
|
Tuberculosis and treatment with infliximab.
|
N Engl J Med
|
2002
|
0.76
|
|
86
|
Local and global spatio-temporal dynamics of HIV-1 subtype F1.
|
J Med Virol
|
2013
|
0.76
|
|
87
|
Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease.
|
New Microbiol
|
2014
|
0.76
|
|
88
|
Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics.
|
Curr HIV Res
|
2016
|
0.76
|
|
89
|
A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era.
|
J Cardiovasc Med (Hagerstown)
|
2015
|
0.76
|
|
90
|
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4.
|
Hepatology
|
2011
|
0.75
|
|
91
|
Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy.
|
BMC Infect Dis
|
2014
|
0.75
|
|
92
|
Intrapulmonary concentrations of cefepime.
|
Crit Care Med
|
2004
|
0.75
|
|
93
|
A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease.
|
J Antimicrob Chemother
|
2008
|
0.75
|
|
94
|
Antibiotic rotation in intensive care units: its usefulness should be demonstrated without pitfalls.
|
Crit Care Med
|
2002
|
0.75
|
|
95
|
A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting.
|
Ther Drug Monit
|
2008
|
0.75
|
|
96
|
Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism.
|
J Antimicrob Chemother
|
2008
|
0.75
|
|
97
|
Disappearance of renal stones in an HIV-1-infected patient after reduction of atazanavir dose.
|
AIDS Res Hum Retroviruses
|
2014
|
0.75
|
|
98
|
Even-order aberration cancellation in quantum interferometry.
|
Phys Rev Lett
|
2008
|
0.75
|
|
99
|
Cytomegalovirus central nervous system compartmentalization in a patient presenting with AIDS.
|
Antivir Ther
|
2014
|
0.75
|
|
100
|
Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.
|
Expert Opin Drug Metab Toxicol
|
2015
|
0.75
|
|
101
|
Magnetic-silica based nucleic acid extraction for Human Immunodeficiency Virus Type-1 drug-resistance testing in low viremic patients.
|
J Clin Virol
|
2009
|
0.75
|
|
102
|
Optimizing HIV therapy. A consensus project on differences between cytidine analogues and regime compactness.
|
New Microbiol
|
2014
|
0.75
|
|
103
|
Does iatrogenic scleroderma due to injection-site reaction to enfuvirtide impair absorption of the drug?
|
Clin Drug Investig
|
2008
|
0.75
|
|
104
|
Efficacy of early pegylated interferon alpha-2b monotherapy for acute hepatitis C in HIV-infected patients.
|
Clin Infect Dis
|
2009
|
0.75
|
|
105
|
Less drug regimens and PI/r-based strategies in HIV infection: focus on best practices using the HIV patient's journey methodology.
|
New Microbiol
|
2014
|
0.75
|
|
106
|
Design and optimization of an adaptive optics system for a high-average-power multi-slab laser (HiLASE).
|
Appl Opt
|
2014
|
0.75
|
|
107
|
No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals.
|
AIDS
|
2014
|
0.75
|
|
108
|
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients.
|
J Antimicrob Chemother
|
2008
|
0.75
|
|
109
|
Interpretation of genotypic resistance to predict darunavir/ritonavir failure in antiretroviral experienced patients.
|
J Acquir Immune Defic Syndr
|
2012
|
0.75
|
|
110
|
Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole.
|
Ther Drug Monit
|
2015
|
0.75
|
|
111
|
Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.
|
Antivir Ther
|
2011
|
0.75
|
|
112
|
Active-grating monochromator for the spectral selection of ultrashort pulses.
|
Opt Express
|
2013
|
0.75
|
|
113
|
Simultaneous determination of rifampicin and efavirenz in plasma.
|
Ther Drug Monit
|
2002
|
0.75
|
|
114
|
Quinine-induced blindness reversed by an increase in alpha1-acid glycoprotein level.
|
Ann Intern Med
|
2002
|
0.75
|
|
115
|
Pulse shaping in the mid-infrared by a deformable mirror.
|
Opt Lett
|
2014
|
0.75
|
|
116
|
No wavefront sensor adaptive optics system for compensation of primary aberrations by software analysis of a point source image. 2. Tests.
|
Appl Opt
|
2007
|
0.75
|
|
117
|
A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients.
|
Braz J Infect Dis
|
2012
|
0.75
|
|
118
|
Surface heating by optical beams and application to mid-infrared imaging.
|
Appl Opt
|
2012
|
0.75
|
|
119
|
No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy.
|
J Med Virol
|
2011
|
0.75
|
|
120
|
Pupil segmentation adaptive optics for invivo mouse retinal fluorescence imaging.
|
Opt Lett
|
2017
|
0.75
|
|
121
|
Zinc selenide-based large aperture photo-controlled deformable mirror.
|
Opt Lett
|
2016
|
0.75
|
|
122
|
Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting.
|
AIDS Res Hum Retroviruses
|
2003
|
0.75
|
|
123
|
Treating advanced HIV infection.
|
J Acquir Immune Defic Syndr
|
2003
|
0.75
|
|
124
|
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop.
|
AIDS Rev
|
2005
|
0.75
|